Coexistence of BCR/ABL1-positive chronic myeloid leukemia and JAK2 V617F-mutated myelofibrosis successfully treated with dasatinib and ruxolitinib

Podobne zapisy

• Concomitant JAK2 V617F-positive polycythemia vera and BCR-ABL-positive chronic myelogenous leukemia treated with ruxolitinib and dasatinib
  od: Zhou, A, i wsp.
  Wydane: (2015)
• Emergence of BCR-ABL1 Chronic Myeloid Leukemia in a JAK2-V617F Polycythemia Vera
  od: Lorenzo, Mariana, i wsp.
  Wydane: (2020)
• Coexistence of JAK2V617F Mutation and BCR–ABL Translocation in a Pregnant Woman with Essential Thrombocythemia
  od: Qin, You-wen, i wsp.
  Wydane: (2014)
• A Case Report of BCR-ABL-JAK2-Positive Chronic Myeloid Leukemia with Complete Hematological and Major Molecular Response to Dasatinib
  od: Ali, Elrazi Awadelkarim Hamid, i wsp.
  Wydane: (2021)
• Dasatinib May Override F317L BCR-ABL Kinase Domain Mutation in Patients with Chronic Myeloid Leukemia
  od: Eşkazan, Ahmet Emre, i wsp.
  Wydane: (2013)